A study has determined that adverse effects leading to treatment discontinuation vary among different blood pressure-lowering drug classes.

Individuals with HIV who were resistant to all four antiretroviral drug classes experienced higher mortality than those who were not resistant, a difference primarily due to lower CD4 cell counts.

First-in-class drugs can be highly innovative because of their novel mechanisms of action, but they also carry uncertainty in the absence of clinical experience. To understand how such drugs advance ...